PureTech has initiated a clinical study to evaluate the safety and effectiveness of its experimental therapy LYT-100 in people with idiopathic pulmonary fibrosis (IPF). “We are excited to be taking this important step towards our goal of helping patients with this devastating condition,” Julie Krop, MD, PureTech’s chief…
Algernon Pharmaceuticals has secured a patent in Canada covering the use of NP-120 (ifenprodil) as a treatment for idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases driven by uncontrolled scarring in the lungs. The patent (No. 3101853), “Compositions and Methods for Treating Idiopathic Pulmonary Fibrosis,” was issued by…
The U.S. Food and Drug Administration (FDA) has given Daewoong Pharmaceutical the go-ahead to start a Phase 2 clinical trial to test the company’s experimental anti-fibrotic medication DWN12088 in people with idiopathic pulmonary fibrosis (IPF). “The existing treatments of Idiopathic pulmonary fibrosis still have high unmet medical needs.
Participants in a Phase 2 trial testing Algernon Pharmaceuticals’ NP-120 (ifenprodil) in people with chronic cough associated with idiopathic pulmonary fibrosis (IPF) have asked to have the experimental medication for their personal use, Algernon announced. The company noted in a press release that it’s “not making any express or…
Cymerus mesenchymal stem cells (MSCs), Cynata Therapeutics’ experimental cell therapy, significantly lowered the levels of pro-inflammatory and pro-scarring molecules in the lungs of a mouse model of idiopathic pulmonary fibrosis (IPF), the company announced. The “highly potent” therapy also was shown to significantly reduce immune cell infiltration, and the…
Mesenchymal stem cells (MSCs) grown in three-dimension (3D) conditions produce tiny extracellular vesicles (EVs) that do not retain the anti-scarring and anti-inflammatory properties seen when they are derived from MSCs grown in two dimensions (2D), a study shows. These findings, obtained from treating a mouse model of pulmonary fibrosis…
The experimental oral therapy AMP945, from Amplia Therapeutics, is as effective as the approved therapy Ofev (nintedanib) at reducing tissue scarring, or fibrosis, in a mouse model of idiopathic pulmonary fibrosis (IPF), the company said. In addition, findings from an already completed Phase 1 trial in healthy…
The National Organization for Rare Disorders’ (NORD) “Living Rare, Living Stronger Patient and Family Forum” is back in person on June 26 for a day of learning and networking in Cleveland, Ohio. The event, which brings together the rare disease community, will take place at the InterContinental Cleveland Conference…
Inconsistent results in the final planned preclinical study of NXP002, Nuformix’s experimental inhaled therapy for idiopathic pulmonary fibrosis (IPF), delayed completion of the preclinical data package needed for a potential advancement into clinical trials. The U.K.-based company, through an outsourced contract research organization (CRO), now plans to conduct additional…
Accord Healthcare has released a generic version of Esbriet (pirfenidone) for people in the U.S. with idiopathic pulmonary fibrosis (IPF). First approved by the U.S. Food and Drug Administration (FDA) in January, the treatment is now available and ready to be shipped, according to Accord. “We’re proud…
Get regular updates to your inbox.
